The use of cholesterol-lowering medications among individuals over 70 in Norway has increased by approximately 90% since 2005, according to the Norwegian Institute of Public Health.
The Norwegian Institute of Public Health (FHI) reports a significant rise in the use of cholesterol-lowering medications among elderly individuals over the age of 70, with the proportion increasing by around 90% since 2005. This upward trend has been consistent over the years, reflecting various underlying factors that contribute to this change. Senior advisor Troy Hammer from FHI notes that an aging population, improved survival rates from cardiovascular diseases, and updated medical guidelines are key contributors to the increased usage of these medications.
In addition to cholesterol-related treatments, there is a broader trend in the growing consumption of medications aimed at preventing heart and vascular diseases among the Norwegian population. FHI highlights that the percentage of the population using at least one medication to treat or prevent such diseases has escalated from 18% in 2005 to an estimated 25% by 2025. This increase signifies a substantial shift in health management practices and a focus on proactive healthcare measures among the aging demographic.
By 2025, nearly 1.4 million individuals in Norway are projected to be using medications for heart and vascular disease management. This increase underscores both the growing health concerns related to cholesterol levels among the elderly and a larger trend towards more comprehensive pharmaceutical interventions aimed at improving cardiovascular health, reflecting changing health priorities in Norway's healthcare system.
